NanoString to Develop Companion Dx for Celgene Lymphoma Drug Study | GenomeWeb

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that it will develop a companion diagnostic test for Celgene's Revlimid (lenalidomide), which the firm is developing for diffuse large B-cell lymphoma.

NanoString said that it will develop the in vitro diagnostic assay for use on its nCounter Analysis System. The assay will be used to screen patients who are being enrolled in a pivotal study of Revlimid for the treatment of DLBCL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.